Orion S.A.OECEarnings & Financial Report
Orion Corporation, founded in 1917 and headquartered at Espoo, Finland, is a globally operating Finnish company which develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients for global markets. All of the company's manufacturing sites and the majority of its R&D units are in Finland.
What changed in Orion S.A.'s 10-K — 2022 vs 2023
Top changes in Orion S.A.'s 2023 10-K
143 paragraphs added · 246 removed · 122 edited across 7 sections
- Item 1A. Risk Factors+80 / −91 · 64 edited
- Item 5. Market for Registrant's Common Equity+10 / −89 · 7 edited
- Item 1. Business+33 / −39 · 33 edited
- Item 7. Management's Discussion & Analysis+5 / −13 · 5 edited
- Item 7A. Quantitative and Qualitative Disclosures About Market Risk+11 / −10 · 10 edited
Item 1. Business
Business — how the company describes what it does
33 edited+0 added−6 removed62 unchanged
Item 1. Business
Business — how the company describes what it does
Item 1A. Risk Factors
Risk Factors — what could go wrong, per management
64 edited+16 added−27 removed81 unchanged
Item 1A. Risk Factors
Risk Factors — what could go wrong, per management
… 27 more changes not shown on this page.
Item 2. Properties
Properties — owned and leased real estate
2 edited+0 added−0 removed0 unchanged
Item 2. Properties
Properties — owned and leased real estate
Item 3. Legal Proceedings
Legal Proceedings — active lawsuits and investigations
1 edited+1 added−1 removed2 unchanged
Item 3. Legal Proceedings
Legal Proceedings — active lawsuits and investigations
Item 5. Market for Registrant's Common Equity
Market for Common Equity — stock, dividends, buybacks
7 edited+3 added−82 removed3 unchanged
Item 5. Market for Registrant's Common Equity
Market for Common Equity — stock, dividends, buybacks
… 12 more changes not shown on this page.
Item 7. Management's Discussion & Analysis
Management's Discussion & Analysis (MD&A) — revenue / margin commentary
5 edited+0 added−8 removed12 unchanged
Item 7. Management's Discussion & Analysis
Management's Discussion & Analysis (MD&A) — revenue / margin commentary
Item 7A. Quantitative and Qualitative Disclosures About Market Risk
Market Risk — interest-rate, FX, commodity exposure
10 edited+1 added−0 removed11 unchanged
Item 7A. Quantitative and Qualitative Disclosures About Market Risk
Market Risk — interest-rate, FX, commodity exposure